Living Cell Technologies opens pig breeding facility ahead of xenotransplantation trials to treat type 1 diabetes.

New model aims to streamline medical device development and aid in gaining regulatory approval.

Australian researchers find that interfering RNA delivered via bacterially-derived minicells can target and kill drug resistant tumours.

Adult muscle stem cells rather than embryonic stem cells could be the key to treating muscular disorders.

Anti-anxiety drug, BNC210, to undergo phase I clinical trial in Adelaide.

Calls for Australian Government to lift moratorium on xenotransplantation so similar trials can occur here.

Hormone adiponectin could be used to better diagnose and treat type 2 diabetes.

CSL to evaluate Phosphagenics' TMP technology with the possibility of an expanded collaboration in the future.

Screening process completed for phase II clinical trial of interferon to treat influenza.

CSIRO has come up with a new technique for repairing knee cartilage by combining chondrocytes with a biodegradable polymer.

A trial of a vaccine for stages II and III melanoma didn't turn out as expected, so the researchers tried it in stage IV patients, causing a few surprises.

The first merger of 2006 has created new opportunities in the hot field of theranostics. Ruth Beran talks with its architects about the merged company and its future plans.

To no one's surprise, CSL has become the dominant force in the Australian biotechnology sector. Graeme O'Neill learns from CSL's chief scientist, Andrew Cuthbertson, about the solid research that will drive the company in the next few years.

The research community is becoming more sophisticated in the way they approach intellectual property and industry partnerships. Ruth Beran looks at how technology transfer has changed, where it is going and the challenges it faces.

Biotechnology has provided a solution to the problem of how to get science to the market without compromising research, writes editor-in-chief Iain Scott.

Kiran Mazumdar-Shaw told AusBiotech 2005 about opportunities for Australian biotech to work with India.

US venture capitalist Osagie Imasogie told AusBiotech 2005 that biotech companies need to get aggressive when it comes to finding opportunities.

Pfizer's Peter Corr told the AusBiotech 2005 conference that big pharma and biotech are part of a delicate ecosystem -- and both have key roles to play.

A pocket of middle Australia on the northern outskirts of Perth is the setting for a proposed biobanking project that even its instigator, Professor Lyle Palmer of the University of Western Australia, calls “ludicrously ambitious”.

A new study has shown that environmental enrichment ameliorates a motor co-ordination deficit in a mouse model of Rett syndrome.

Epigenetics is moving from the laboratory to the clinic and the pharmacy, with several histone deacetylase inhibitors on the market and epigenetic screening likely to become as widespread as genetic screening.

For such a simple idea, it’s a surprise that no one has thought of it before. An automated system for streaking agar plates is on the market, developed here in Australia.

The Clinical Research Excellence (CRX08) conference starts in Brisbane tomorrow. We talk flu pandemics with plenary speaker Anne Kelso.

Professor Alan Cowman of the Walter and Eliza Hall Institute will deliver the Rubbo Oration at this year's Australian Society of Microbiology (ASM) annual meeting, being held in Melbourne next week.

The Sydney Project aims to have human embryonic stem cells in clinical trials to treat type 1 diabetes in four years.

Biochemical geneticist Kevin Carpenter discusses how he helped tracked down the blip in the Bindeez beads.

Sydney-based Narhex has begun recruiting for an early-stage trial of an HIV drug. Helen Schuller spoke with the company's MD, John Mills, about HIV drug development, working in China, and good management.

When you think of the Human Genome Project, images of banks of sequencing machines pumping out millions of base pairs of information comes to mind. According to Dr John Barlow, Melbourne divisional manager of the Australian Genome Research Facility, state-of-the-art sequencing is still largely electrophoresis-based. However, sequencers have come a long way since the days of pouring your own sequencing gel and using radioactive dideoxynucleotides.

Capillary electrophoresis (CE) is a technique that allows researchers to separate analytes based on their differential mobilities in aqueous media when an electric field is applied.

Sample capacity is at the heart of the decision on what capillary electrophoresis system best fits a lab's needs.